CoreCivic, Inc.
CXW is being valued as if the recent ICE-driven earnings step-up is fragile, but FY26 guidance, idle bed optionality, and a more active capital return stance support materially higher earnings power than the market is fully crediting.
The market is still underestimating how much earnings power has changed. FY2025 looked ordinary on the surface, with revenue down 0.8% and operating margin easing to 9.3%, but the more relevant data point is the current year guide. Management now expects $1.53 to $1.63 of adjusted EPS and $453.8M to $461.8M of adjusted EBITDA for FY26, both raised after Q1, even though ICE populations dipped and cut the prior earnings outlook by $0.09 to $0.15 per share. That is not the pattern of a business rolling over.
The first thing the case depends on is utilization. Q1 adjusted EBITDA rose 36% YoY to $110.1M, with margin at 18.0%, driven by four reactivated facilities, higher ICE demand, and state population growth. CoreCivic still has five idle facilities and 7,066 beds available. That embedded capacity matters because the company does not need a heroic capex cycle to grow if federal or state demand strengthens. The second thing the case depends on is management delivering through volatility. The company has posted 8 straight quarterly EPS beats, including a +28.8% beat in the latest quarter, and management raised full-year guidance while openly flagging that Q2 would step down sequentially.
What keeps conviction low is simple. This is a politically exposed business with lumpy demand, and the stock is no longer cheap on the obvious metric. At 26.38x trailing P/E, CXW already trades above the 21.4x peer average, and the shares are just 4.1% below the high after a 52.6% three-month run. Balance-sheet risk is manageable, not trivial, at 4.01x debt/EBITDA with $1.4B of debt, and cash flow quality remains weak.
The opportunity is that the market may still be anchoring on the wrong base. If FY26 earnings become the new normal rather than a temporary spike, today’s valuation is not stretched. If ICE utilization disappoints for longer, the setup gets much harder because a lot of the rerating has already happened. That makes CXW a BUY, but only for investors willing to own a policy-sensitive name into a catalyst-heavy next few quarters.
ICE populations recover faster than guided, more idle capacity is activated, buybacks continue, and EPS lands above the top end with a premium multiple on improved durability.
Management delivers near the midpoint of FY26 guidance, Midwest Regional and Clinical Solutions offset ICE volatility, and investors pay up for visibly higher earnings power.
ICE populations stay weak, Q2 weakness extends into 2H26, and the market values CXW closer to DCF-style downside with leverage and policy risk back in focus.
Quant call aligns with analyst consensus (Strong Buy: 2 buy / 0 hold / 0 sell).
The single greatest edge an investor can have is a long-term orientation.
FY26 earnings power is moving to $1.53 to $1.63 EPS, which puts the stock at roughly a low-20s forward P/E versus a 26.38x trailing P/E, so the valuation compresses if management simply delivers its current guide. The moat is still based on licensed capacity, government relationships, and the ability to reactivate existing facilities faster than a new entrant can build them, and the 7,066 idle beds make that moat more relevant over the next 3 to 5 years if detention demand stays elevated. AI is not a direct growth engine here, but it can help staffing, scheduling, healthcare workflows, and compliance costs at the margin; regulation matters far more than technology, and that keeps conviction low even with the improved earnings path. The core forward question is whether CXW is becoming a steadier cash-generating operator or just catching a temporary federal demand spike.
- FY26 adjusted EPS guidance of $1.53 to $1.63 implies roughly 40% to 50% growth from FY2025 EPS of $1.09
- Q1 FY26 adjusted EBITDA reached $110.1M, up 36% YoY, with margin expanding to 18.0% from 15.9% a year earlier
- CoreCivic still has five idle facilities and 7,066 beds available, creating embedded capacity for federal or state demand without needing major greenfield spend
- Management raised FY26 adjusted EBITDA guidance to $453.8M to $461.8M from $437M to $445M even after lowering the ICE outlook, showing that Midwest Regional activation and Clinical Solutions are already offsetting some volatility.
- The earnings track record is strong, with 8 straight quarterly EPS beats since early 2024, including +28.8% in May 2026, +28.6% in May 2025, and +34.4% in November 2024.
- Federal revenue grew 48% YoY in Q1 FY26 as ICE revenue nearly doubled, confirming that the federal channel still has real operating leverage when populations rise.
- Capital return has turned more shareholder-friendly, with 2.3M shares repurchased in Q1 FY26 for $44.7M, and management explicitly saying buybacks remain a priority.
- Valuation is no longer cheap on earnings, with CXW at 26.38x P/E versus peers at 21.4x, while the quant engine flags wide peer dispersion of 8.8x, reducing confidence in multiple-based upside.
- FY2025 revenue fell 0.8% YoY and operating margin slipped to 9.3% from 9.6%, so the story still depends more on utilization recovery than on broad-based organic growth.
- Management warned that Q2 will show a sequential EPS decline after ICE populations fell by about 3,000 from the January peak through April 30, and the lower ICE forecast cut $0.09 to $0.15 per share versus prior expectations.
- Leverage is not trivial for a business with policy-sensitive demand, at 4.01x debt/EBITDA and $1.4B of total debt, while cash flow quality is weak with a sub-score of 4 and FY2025 FCF at roughly breakeven.
| Metric | Value | Context |
|---|---|---|
| Current price | $31.35 | Reference price for the quant target |
| Quant price target | $50.13 | Low confidence, 59.9% upside, basis: earnings_growth_blend |
| FY2025 revenue | $2.2B | -0.8% YoY, showing limited growth before the FY26 step-up |
| FY2025 EPS | $1.09 | +24.6% YoY, strongest trailing proof of improving earnings power |
| FY2025 operating margin | 9.3% | Down from 9.6% in the prior year |
| Valuation | P/E 26.38x | P/S 1.42x | P/B 2.38x | P/E above peers, P/S well below peer avg 5.4x |
| FY26 guidance | Adj. EPS $1.53-$1.63 | Adj. EBITDA $453.8M-$461.8M | Raised after Q1 despite weaker near-term ICE populations |
| Q1 FY26 EBITDA | $110.1M | +36% YoY, margin 18.0%, up 210 bps YoY |
| Leverage | Debt/EBITDA 4.01x | Debt/Equity 1.00x | Total debt $1.4B | Manageable, but elevated for a policy-sensitive business |
| Capital returns | Buybacks $0.1B | Includes 2.3M shares repurchased for $44.7M in Q1 FY26 |
| 52-week position | $15.74-$32.69 | Current price is -4.1% from high and 50.0% above 200-day average |
The biggest risk is that the assumed 2H26 ICE recovery does not materialize, because management already said the lower ICE forecast reduced earnings by $0.09 to $0.15 per share versus prior expectations.
Q2 2026 earnings on August 5, 2026, especially the read on ICE populations, Midwest Regional ramp, and whether FY26 guidance is maintained after the expected Q2 step-down.
Positioning is not euphoric despite the sharp rally. Short interest is only 1.89%, or 1.81M shares, down 35.4%, with 1.5 days-to-cover, so this is not a classic squeeze setup and a lot of the easy pain trade may already be spent. Institutional ownership is concentrated, with the top three holders at 65.2%, which can support stability, and the near-dated options backdrop is described as positive gamma, which usually dampens volatility rather than fuels a breakout.
Largest earnings driver, tied to federal, state, and local detention populations; Q1 FY26 strength came from ICE demand, reactivated facilities, and state population growth.
Occupancy-sensitive segment that benefited in 2024 from higher resident counts and lower labor costs; still part of the operating leverage story but less visible in the latest call than federal detention.
Smaller and less central after prior lease expirations, with limited recent growth contribution versus the operating segments.
Acquired for $148M, expected to add $0.03 to $0.05 EPS net of interest in FY26 and diversify earnings modestly beyond detention utilization.
FY26 guidance was raised despite a temporary Q2 ICE population dip.
Execution has been better than skeptics expected. On the 2024 Q2 call, management guided to $0.58 to $0.66 adjusted EPS and $162.4M to $172.4M AFFO for FY2024 while warning that South Texas would pressure margins by 150 to 200 bps after the August 9, 2024 termination. Since then, the company has delivered 8 straight EPS beats, FY2025 EPS grew to $1.09, and FY26 adjusted EPS guidance has risen to $1.53 to $1.63 with adjusted EBITDA at $453.8M to $461.8M. The strategic direction has changed in one important way: in 2024 the message was debt reduction first, while in 2026 the company is buying back stock and adding the $148M Clinical Solutions Pharmacy acquisition. That shift is credible because operating margins and EBITDA have recovered, but it also means management is now leaning more aggressively into capital deployment than it was two years ago.
Even with this reduction, we are increasing our full-year guidance reflecting our strategic investment in Clinical Solutions and the successful activation of our Midwest Regional Reception Center, which more than offset the decline in our updated forecast for ICE populations.
We expect adjusted EBITDA of $453.8 million to $461.8 million, up from $437 million to $445 million.
While we are pleased with the first quarter results, we expect a sequential decline in per-share results in the second quarter as a result of the recent reduction in nationwide ICE detention population.
Adjusted EPS exceeded average analyst estimates by $0.12 per share and adjusted EBITDA exceeded average analyst estimates by $13.3 million.
Therefore, our guidance reflects growth in ICE populations under existing contracts during the second half of the year.
The moat is not brand, it is controlled capacity and contracting infrastructure. CoreCivic already owns or controls specialized facilities, has compliance systems built for government customers, and still has 7,066 idle beds that can be activated faster than a competitor can permit and build new supply. That advantage is durable over the next few years, but it is only as valuable as policy demand, so the moat is operationally real and politically conditional.
Capital allocation has clearly shifted since 2024. Two years ago management said, "Accordingly, in order to minimize the impact on leverage, we intend to prioritize the use of our free cash flow to further reduce our debt ahead of stock repurchases," but in FY26 Q1 it repurchased 2.3M shares for $44.7M and said buybacks remain a priority. That is reasonable if EBITDA really steps up into the $453.8M to $461.8M range, but with FY2025 FCF roughly breakeven and leverage at 4.01x debt/EBITDA, discipline still matters more than aggressiveness.
CXW rates a BUY at Low conviction. The stock is no longer undiscovered, but the earnings base is moving up faster than many investors likely expected, and FY26 guidance supports more upside if utilization normalizes in the second half. The key debate is durability, not whether Q1 was strong. A downgrade to HOLD would require evidence that 2H26 ICE recovery is not happening or that EBITDA falls short of the $453.8M to $461.8M guide. A move to higher conviction would require cleaner cash conversion and leverage improvement from the current 4.01x debt/EBITDA.
≣ Full research note tap to expand
Executive Summary
BUY, Low conviction. Rated BUY, Low conviction. The stock has already rerated hard, up 52.6% in 3 months and sitting 4.1% below its 52-week and 5-year high, so this is no longer an early setup. Even so, management raised FY26 guidance to $1.53 to $1.63 adjusted EPS and $453.8M to $461.8M adjusted EBITDA despite a temporary ICE population dip, which keeps upside alive if 2H26 utilization recovers as guided.
Investment Thesis
The market is still underestimating how much earnings power has changed. FY2025 looked ordinary on the surface, with revenue down 0.8% and operating margin easing to 9.3%, but the more relevant data point is the current year guide. Management now expects $1.53 to $1.63 of adjusted EPS and $453.8M to $461.8M of adjusted EBITDA for FY26, both raised after Q1, even though ICE populations dipped and cut the prior earnings outlook by $0.09 to $0.15 per share. That is not the pattern of a business rolling over.
The first thing the case depends on is utilization. Q1 adjusted EBITDA rose 36% YoY to $110.1M, with margin at 18.0%, driven by four reactivated facilities, higher ICE demand, and state population growth. CoreCivic still has five idle facilities and 7,066 beds available. That embedded capacity matters because the company does not need a heroic capex cycle to grow if federal or state demand strengthens. The second thing the case depends on is management delivering through volatility. The company has posted 8 straight quarterly EPS beats, including a +28.8% beat in the latest quarter, and management raised full-year guidance while openly flagging that Q2 would step down sequentially.
What keeps conviction low is simple. This is a politically exposed business with lumpy demand, and the stock is no longer cheap on the obvious metric. At 26.38x trailing P/E, CXW already trades above the 21.4x peer average, and the shares are just 4.1% below the high after a 52.6% three-month run. Balance-sheet risk is manageable, not trivial, at 4.01x debt/EBITDA with $1.4B of debt, and cash flow quality remains weak.
The opportunity is that the market may still be anchoring on the wrong base. If FY26 earnings become the new normal rather than a temporary spike, today’s valuation is not stretched. If ICE utilization disappoints for longer, the setup gets much harder because a lot of the rerating has already happened. That makes CXW a BUY, but only for investors willing to own a policy-sensitive name into a catalyst-heavy next few quarters.
Key Metrics
| Metric | Value | Context | ||
|---|---|---|---|---|
| Current price | $31.35 | Reference price for the quant target | ||
| Quant price target | $50.13 | Low confidence, 59.9% upside, basis: earnings_growth_blend | ||
| FY2025 revenue | $2.2B | -0.8% YoY, showing limited growth before the FY26 step-up | ||
| FY2025 EPS | $1.09 | +24.6% YoY, strongest trailing proof of improving earnings power | ||
| FY2025 operating margin | 9.3% | Down from 9.6% in the prior year | ||
| Valuation | P/E 26.38x | P/S 1.42x | P/B 2.38x | P/E above peers, P/S well below peer avg 5.4x |
| FY26 guidance | Adj. EPS $1.53-$1.63 | Adj. EBITDA $453.8M-$461.8M | Raised after Q1 despite weaker near-term ICE populations | |
| Q1 FY26 EBITDA | $110.1M | +36% YoY, margin 18.0%, up 210 bps YoY | ||
| Leverage | Debt/EBITDA 4.01x | Debt/Equity 1.00x | Total debt $1.4B | Manageable, but elevated for a policy-sensitive business |
| Capital returns | Buybacks $0.1B | Includes 2.3M shares repurchased for $44.7M in Q1 FY26 | ||
| 52-week position | $15.74-$32.69 | Current price is -4.1% from high and 50.0% above 200-day average |
Financial Strength
The balance sheet is adequate, not a source of comfort. Current ratio at 2.44 gives near-term liquidity room, but leverage at 4.01x debt/EBITDA and $1.4B of debt means the business still needs EBITDA to hold up. Margin direction is better than trailing FY2025 suggests, because Q1 FY26 EBITDA margin reached 18.0%, but the weak cash flow quality score and roughly breakeven FY2025 FCF argue against treating that margin improvement as fully de-risked yet.
Competitive Position
The moat is not brand, it is controlled capacity and contracting infrastructure. CoreCivic already owns or controls specialized facilities, has compliance systems built for government customers, and still has 7,066 idle beds that can be activated faster than a competitor can permit and build new supply. That advantage is durable over the next few years, but it is only as valuable as policy demand, so the moat is operationally real and politically conditional.
Management & Guidance
Management has earned some credibility on near-term forecasting. The latest call explicitly warned that, "While we are pleased with the first quarter results, we expect a sequential decline in per-share results in the second quarter as a result of the recent reduction in nationwide ICE detention population," while still raising the full-year view. The most important line was, "We expect adjusted EBITDA of $453.8 million to $461.8 million, up from $437 million to $445 million." Given the company's recent beat streak and the fact that the raised guide already absorbs a lower ICE forecast, the guidance looks realistic, though still dependent on the assumption that, "Therefore, our guidance reflects growth in ICE populations under existing contracts during the second half of the year."
Segment Analysis
- Safety (N/A): Largest earnings driver, tied to federal, state, and local detention populations; Q1 FY26 strength came from ICE demand, reactivated facilities, and state population growth.
- Community (N/A): Occupancy-sensitive segment that benefited in 2024 from higher resident counts and lower labor costs; still part of the operating leverage story but less visible in the latest call than federal detention.
- Property (N/A): Smaller and less central after prior lease expirations, with limited recent growth contribution versus the operating segments.
- Clinical Solutions Pharmacy ($215M-$230M FY26 revenue guide): Acquired for $148M, expected to add $0.03 to $0.05 EPS net of interest in FY26 and diversify earnings modestly beyond detention utilization.
Capital Allocation
Capital allocation has clearly shifted since 2024. Two years ago management said, "Accordingly, in order to minimize the impact on leverage, we intend to prioritize the use of our free cash flow to further reduce our debt ahead of stock repurchases," but in FY26 Q1 it repurchased 2.3M shares for $44.7M and said buybacks remain a priority. That is reasonable if EBITDA really steps up into the $453.8M to $461.8M range, but with FY2025 FCF roughly breakeven and leverage at 4.01x debt/EBITDA, discipline still matters more than aggressiveness.
Management Execution & Track Record
Execution has been better than skeptics expected. On the 2024 Q2 call, management guided to $0.58 to $0.66 adjusted EPS and $162.4M to $172.4M AFFO for FY2024 while warning that South Texas would pressure margins by 150 to 200 bps after the August 9, 2024 termination. Since then, the company has delivered 8 straight EPS beats, FY2025 EPS grew to $1.09, and FY26 adjusted EPS guidance has risen to $1.53 to $1.63 with adjusted EBITDA at $453.8M to $461.8M. The strategic direction has changed in one important way: in 2024 the message was debt reduction first, while in 2026 the company is buying back stock and adding the $148M Clinical Solutions Pharmacy acquisition. That shift is credible because operating margins and EBITDA have recovered, but it also means management is now leaning more aggressively into capital deployment than it was two years ago.
Positioning & Flows
Positioning is not euphoric despite the sharp rally. Short interest is only 1.89%, or 1.81M shares, down 35.4%, with 1.5 days-to-cover, so this is not a classic squeeze setup and a lot of the easy pain trade may already be spent. Institutional ownership is concentrated, with the top three holders at 65.2%, which can support stability, and the near-dated options backdrop is described as positive gamma, which usually dampens volatility rather than fuels a breakout.
Bull Case
- Management raised FY26 adjusted EBITDA guidance to $453.8M to $461.8M from $437M to $445M even after lowering the ICE outlook, showing that Midwest Regional activation and Clinical Solutions are already offsetting some volatility.
- The earnings track record is strong, with 8 straight quarterly EPS beats since early 2024, including +28.8% in May 2026, +28.6% in May 2025, and +34.4% in November 2024.
- Federal revenue grew 48% YoY in Q1 FY26 as ICE revenue nearly doubled, confirming that the federal channel still has real operating leverage when populations rise.
- Capital return has turned more shareholder-friendly, with 2.3M shares repurchased in Q1 FY26 for $44.7M, and management explicitly saying buybacks remain a priority.
Bear Case
- Valuation is no longer cheap on earnings, with CXW at 26.38x P/E versus peers at 21.4x, while the quant engine flags wide peer dispersion of 8.8x, reducing confidence in multiple-based upside.
- FY2025 revenue fell 0.8% YoY and operating margin slipped to 9.3% from 9.6%, so the story still depends more on utilization recovery than on broad-based organic growth.
- Management warned that Q2 will show a sequential EPS decline after ICE populations fell by about 3,000 from the January peak through April 30, and the lower ICE forecast cut $0.09 to $0.15 per share versus prior expectations.
- Leverage is not trivial for a business with policy-sensitive demand, at 4.01x debt/EBITDA and $1.4B of total debt, while cash flow quality is weak with a sub-score of 4 and FY2025 FCF at roughly breakeven.
Valuation & Price Target
Engine price target $50.13 (+59.9% vs current), Low confidence.
- P/E Multiple: $21.15 (28% weight)
- P/S Multiple: $118 (20% weight)
- Quality-adjusted: $34.94 (20% weight)
- DCF: $22.15 (9% weight)
This analysis stays with the quant baseline of BUY, but with Low conviction for the same reason the engine confidence is low. The quant target is $50.13, supported by a quality-adjusted value of $34.94 and a DCF of $22.15, while the $118 P/S output is obviously not a sensible anchor for this business and the peer-based approach is weakened by the 8.8x dispersion in comparable P/Es. The case for buying does not rest on sell-side consensus, which is only 2 buys and therefore low signal; it rests on the fact that guided FY26 EPS of $1.53 to $1.63 materially exceeds FY2025's $1.09, and recent execution has repeatedly beaten expectations. The low conviction comes from policy sensitivity, a stock already near highs, and leverage at 4.01x debt/EBITDA.
Risk Assessment
Risk score 35/100 (Low). The biggest risk is that the assumed 2H26 ICE recovery does not materialize, because management already said the lower ICE forecast reduced earnings by $0.09 to $0.15 per share versus prior expectations.
The Bottom Line
CXW rates a BUY at Low conviction. The stock is no longer undiscovered, but the earnings base is moving up faster than many investors likely expected, and FY26 guidance supports more upside if utilization normalizes in the second half. The key debate is durability, not whether Q1 was strong. A downgrade to HOLD would require evidence that 2H26 ICE recovery is not happening or that EBITDA falls short of the $453.8M to $461.8M guide. A move to higher conviction would require cleaner cash conversion and leverage improvement from the current 4.01x debt/EBITDA.
Go deeper in the app
Live charts, options analytics, the full earnings-call breakdown, price alerts, and every other stock — updated in real time.
Get Tickr